Tumor Necrosis Factor Blockade for Treatment of Inflammatory Bowel Disease: Efficacy and Safety

Current Molecular Pharmacology

Volumn 3, Issue 3, 2010, Pages 145-152

  Ngo, Benjamin ^a   Farre, Christopher P ^a   Barr, Maura ^a   Wolov, Kevin ^a   Bailey, Robert ^a   Mullin, James M ^a,b   Thornton, James J ^a  

^a LANKENAU HOSPITAL   (United States)

^b LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

Adalimumab; Certolizumab; Crohn's disease; Epithelial tight junctions; Inflammatory bowel disease; Infliximab; Tumor necrosis factor; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; INFLIXIMAB; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR;

APOPTOSIS; ARTICLE; CLINICAL TRIAL; CROHN DISEASE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED CANCER; DRUG PROTEIN BINDING; DRUG SAFETY; ENTERITIS; HUMAN; IMMUNE SYSTEM; IMMUNOGENICITY; INFECTION; INJECTION SITE REACTION; MONOTHERAPY; PRIORITY JOURNAL; TIGHT JUNCTION; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

EID: 78649988873     PISSN: 18744672     EISSN: 18744702     Source Type: Journal    
DOI: 10.2174/1874467211003030145     Document Type: Article

References (79)

1. Kirsner, J.B. Historical aspects of inflammatory bowel disease. J. Clin. Gastroenterol., 1988, 10(3), 286-297.
2. Loftus, E.V. Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology, 2004, 126(6), 1504-1517.
3. Ramcharan, S.; Pellegrin, F.A.; Ray, R.M.; Hsu, J.P. The Walnut Creek Contraceptive Drug Study. A prospective study of the side effects of oral contraceptives. Volume III, an interim report: A comparison of disease occurrence leading to hospitalization or death in users and nonusers of oral contraceptives. J. Reprod. Med., 1980, 25(Suppl. 6), 345-372.
4. Geerling, B.J.; Dagnelie, P.C.; Badart-Smook, A.; Russel, M. G.; Stockbrügger, R.W.; Brummer, R.J. Diet as a risk factor for the development of ulcerative colitis. Am. J. Gastroenterol., 2000, 95(4), 1008-1013.
5. Rigas, A.; Rigas, B.; Glassman, M.; Yen, Y.Y.; Lan, S.J.; Petridou, E.; Hsieh, C.C.; Trichopoulos, D. Breast-feeding and maternal smoking in the etiology of Crohn's disease and ulcerative colitis in childhood. Ann. Epidemiol., 1993, 3(4), 387-392.
6. Halfvarson, J.; Bodin, L.; Tysk, C.; Lindberg, E.; Järnerot, G. Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics. Gastroenterology, 2003, 124(7), 1767-1773.
7. Harries, A.D.; Baird, A.; Rhodes, J. Non-smoking: a feature of ulcerative colitis. Br. Med. J. (Clin. Res. Ed.). 1982, 284(6317), 706.
8. Gilat, T.; Hacohen, D.; Lilos, P.; Langman, M.J. Childhood factors in ulcerative colitis and Crohn's disease. An international cooperative study. Scand. J. Gastroenterol., 1987, 22(8), 1009-1024.
9. Hanauer, S.B. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm. Bowel Dis., 2006, 12(Suppl. 1), S3-S9.
10. Barrett, J.C.; Hansoul, S.; Nicolae, D.L.; Cho, J.H.; Duerr, R. H.; Rioux, J.D.; Brant, S.R.; Silverberg, M.S.; Taylor, K.D.; Barmada, M.M.; Bitton, A.; Dassopoulos, T.; Datta, L.W.; Green, T.; Griffiths, A.M.; Kistner, E.O.; Murtha, M.T.; Regueiro, M.D.; Rotter, J.I.; Schumm, L.P.; Steinhart, A.H.; Targan, S.R.; Xavier, R.J.; NIDDK IBD Genetics Consortium;
11. Libioulle C.; Sandor, C.; Lathrop, M.; Belaiche, J.; Dewit, O.; Gut, I.; Heath, S.; Laukens, D.; Mni, M.; Rutgeerts, P.; Van Gossum, A.; Zelenika, D.; Franchimont, D.; Hugot, J.P.; de Vos, M.; Vermeire, S.; Louis, E.; Belgian-French IBD Consortium; Wellcome Trust Case Control Consortium;
12. Cardon, L.R.; Anderson, C.A.; Drummond, H.; Nimmo, E.; Ahmad, T.; Prescott, N.J.; Onnie, C.M.; Fisher, S.A.; Marchini, J.; Ghori, J.; Bumpstead, S.; Gwilliam, R.; Tremelling, M.; Deloukas, P.; Mansfield, J.; Jewell, D.; Satsangi, J.; Mathew, C.G.; Parkes, M.; Georges, M.; Daly, M.J. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat. Genet., 2008, 40(8), 955-962.
13. Hampe, J.; Cuthbert, A.; Croucher, P.J.; Mirza, M.M.; Mascheretti, S.; Fisher, S.; Frenzel, H.; King, K.; Hasselmeyer, A.; MacPherson, A.J.; Bridger, S.; van Deventer, S.; Forbes, A.; Nikolaus, S.; Lennard-Jones, J.E.; Foelsch, U.R.; Krawczak, M.; Lewis, C.; Schreiber, S.; Mathew, C.G. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet, 2001, 357(9272), 1925-1928.
14. Fiocchi, C.; Battisto, J.R.; Farmer, R.G. Studies on isolated gut mucosal lymphocytes in inflammatory bowel disease. Detection of activated T cells and enhanced proliferation to Staphylococcus aureus and lipopolysaccharides. Dig. Dis. Sci., 1981, 26(8), 728-736.
15. Hollander, D.; Vadheim, C.M.; Brettholz, E.; Petersen, G.M.; Delahunty, T.; Rotter, J.I. Increased intestinal permeability in patients with Crohn's disease and their relatives. A possible etiologic factor. Ann. Intern. Med., 1986, 105, 883-885.
16. Ligumsky Karmeli, F.; Sharon, P.; Zor, U.; Cohen, F.; Rachmilewitz, D. Enhanced thromboxane A2 and prostacyclin production by cultured rectal mucosa in ulcerative colitis and its inhibition by steroids and sulfasalazine. Gastroenterology, 1981, 81(3), 444-449.
17. Sharon, P.; Ligumsky, M.; Rachmilewitz, D.; Zor, U. Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology, 978, 75(4), 638-640.
18. Shanahan, F.; Niederlehner, A.; Carramanzana, N.; Anton, P. Sulfasalazine inhibits the binding of TNF alpha to its receptor. Immunopharmacology, 1990, 20(3), 217-224.
19. Schreiber, S.; Nikolaus, S.; Hampe, J. Activation of nuclear factor kappa B inflammatory bowel disease. Gut, 1998, 42(4), 477-484.
20. Soler, A.P.; Marano, C.W.; Bryans, M.; Miller, R.D.; Garulacan, L.A.; Mauldin, S.K.; Stamato, T.D.; Mullin, J.M. Activation of NFkappaB is necessary for the restoration of the barrier function of an epithelium undergoing TNF-alpha-induced apoptosis. Eur. J. Cell Biol., 1999, 78(1), 56-66.
21. Ye, D.; Ma, I.; Ma, T.Y. Molecular mechanism of tumor necrosis factor-alpha modulation of intestinal epithelial tight junction barrier. Am. J. Physiol. Gastrointest. Liver Physiol., 2006, 290(3), G496-504.
22. Zettl, K.S.; Sjaastad, M.D.; Riskin, P.M.; Parry, G.; Machen, T.E.; Firestone, G.L. Glucocorticoid-induced formation of tight junctions in mouse mammary epithelial cells in vitro. Proc. Natl. cad. Sci. USA, 1992, 89(19), 9069-9073.
23. Porvaznik, M.; Johnson, R.G.; Sheridan, J.D. Tight junction development between cultured hepatoma cells: possible stages in assembly and enhancement with dexamethasone. J. Supramol. Struct., 1979, 10(1), 13-30.
24. Swann, P.F.; Waters, T.R.; Moulton, D.C.; Xu, Y.Z.; Zheng, Q.; Edwards, M.; Mace, R. Role of streplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science, 1996, 273(5278), 1109.
25. Black, R.A.; Rauch, C.T.; Kozlosky, C.J.; Peschon, J.J.; Slack, J.L.; Wolfson, M.F.; Castner, B.J.; Stocking, K.L.; Reddy, P.; Srinivasan, S.; Nelson, N.; Boiani, N.; Schooley, K.A.; Gerhart, M.; Davis, R.; Fitzner, J.N.; Johnson, R.S.; Paxton, R.J.; March, C.J.; Cerretti, D.P. A metalloproteinase disintegrin that releases tumournecrosis factor-alpha from cells. Nature, 1997, 385, 729-733.
26. Wajant, H.; Pfizenmaier, K.; Scheurich, P. Tumor necrosis factor signaling. Cell Death Differ., 2003, 10, 45-65.
27. Dinarello, C.A. Proinflammatory cytokines. Chest, 2000, 118, 503-508.
28. Guy-Grand, D.; DiSanto, J.P.; Henchoz, P.; Malassis-Séris, M.; Vassalli, P. Small bowel enteropathy: role of intraepithelial lymphocytes and of cytokines in the induction of epithelial cell death and renewal. Eur. J. Immunol., 1998, 28, 730-744.
29. Mullin, J.M.; Laughlin, K.V.; Marano, C.W.; Russo, L.M.; Soler, A.P. Modulation of tumor necrosis factor-induced increase in renal (LLC-PK1) transepithelial permeability. Am. J. Physiol., 1992, 263, F915-F924.
30. Marano, C.W.; Lewis, S.A.; Garulacan, L.A.; Soler, A.P.; Mullin J.M. Tumor necrosis factor-alpha increases sodium and chloride conductance across the tight junction of CACO-2 BBE, a human intestinal epithelial cell line. J. Membr. Biol., 1998, 161, 263-274.
31. Gitter, A.H.; Bendfeldt, K.; Schulzke, J.D.; Fromm M. Leaks in the epithelial barrier caused by spontaneous and TNF-alpha-induced single-cell apoptosis. FASEB J., 2000, 14, 1749-1753.
32. Bruewer, M.; Luegering, A.; Kucharzik, T.; Parkos, C.A.; Madara, J.L.; Hopkins, A.M.; Nusrat, A. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J. Immunol., 2003, 171, 6164-6172.
33. Mankertz, J.; Tavalali, S.; Schmitz, H.; Mankertz, A.; Riecken, E.O.; Fromm, M.; Schulzke, J.D. Expression from the human occluding promoter is affected by tumor necrosis factor alpha and interferon gamma. J. Cell Sci., 2000, 113, 2085-2090.
34. Murch, S.H.; Lamkin, V.A.; Savage, M.O.; Walker-Smith, J.A.; MacDonald, T.T. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut, 1991, 32, 913-917.
35. Reinecker, H.C.; Steffen, M.; Witthoeft, T.; Pflueger, I.; Schreiber, S.; MacDermott, R.P.; Raedler, A. Enhanced secretion of tumor necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin. Exp. Immunol., 1993, 94, 171-181.
36. Braegger, C.P.; Nicholls, S.; Murch, S.H.; Stephens McDonald, T.T. Tumor necrosis factor in stool as a marker of intestinal inflammation. Lancet, 1992, 339, 89-91.
37. Mullin, J.M.; Snock, K.V. Effect of tumor necrosis factor on epithelial tight junctions and transepithelial permeability. Cancer Res., 1990, 50(7), 2172-2176.
38. Larrick, J.W.; Wright, S.C. Cytotoxic mechanism of tumor necrosis factor-alpha. FASEB J., 1990, 4(14), 3215-3223.
39. Laster, S.M.; Wood, J.G.; Gooding, L.R. Tumor necrosis factor can induce both apoptic and necrotic forms of cell lysis. J. Immunol., 1988, 141(8), 2629-2634.
40. Mullin, J.M.; Marano, C.W.; Laughlin, K.V.; Nuciglio, M.; Stevenson, B.R.; Soler, P. Different size limitations for increased transepithelial paracellular solute flux across phorbol ester and tumor necrosis factor-treated epithelial cell sheets. J. Cell Physiol., 1997, 171(2), 226-233.
41. Peralta Soler, A.; Mullin, J.M.; Knudsen, K.A.; Marano, C.W. Tissue remodeling during tumor necrosis factor-induced apoptosis in LLC-PK1 renal epithelial cells. Am. J. Physiol., 1996, 270(5 Pt. 2), F869-879.
42. Schmitz, H.; Fromm, M.; Bentzel, C.J.; Scholz, P.; Detjen, K.; Mankertz, J.; Bode, H.; Epple, H.J.; Riecken, E.O.; Schulzke, J.D. Tumor necrosis factor-alpha (TNFalpha) regulates the epithelial barrier in the human intestinal cell line HT-29/B6. J. Cell Sci., 1999, 112(Pt 1), 137-146.
43. Janeway, C.A.; Travers, P.; Walport, M.; Shlomchik, M. Immunobiology, 5th ed.; Garland Publishing, 2001.
44. Van den Brande, J.M.; Braat, H.; van den Brink, G.R.; Versteeg, H.H.; Bauer, C.A.; Hoedemaeker, I.; van Montfrans, C.; Hommes, D.W.; Peppelenbosch, M.P.; van Deventer, S.J. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology, 2003, 124(7), 1774-1785.
45. Marini, M.; Bamias, G.; Rivera-Nieves, J.; Moskaluk, C.A.; Hoang, S.B.; Ross, W.G.; Pizarro, T.T.; Cominelli, F. TNF-alpha neutralization ameliorates the severity of murine Crohn's-like ileitis by abrogation of intestinal epithelial cell apoptosis. Proc. Natl. Acad. Sci. USA, 2003, 100(14), 8366-8371.
46. Knight, D.M.; Trinh, H.; Le, J.; Siegel, S.; Shealy, D.; McDonough, M.; Scallon, B.; Moore, M.A.; Vilcek, J.; Daddona, P. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol. Immunol., 1993, 30, 1443-1453.
47. Kodera, Y.; Matsushima, A.; Hiroto, M.; Nishimura, H.; Ishii, A.; Ueno, T.; Inada, Y. Pegylation of proteins and bioactive substances for medical and technical applications. Prog. Polym. Sci., 1998, 23(7), 1233-1271.
48. Targan, S.R.; Hanauer, S.B.; van Deventer, S.J.; Mayer, L.; Present, D.H.; Braakman, T.; DeWoody, K.L.; Schaible, T.F.; Rutgeerts, P.J. A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease. N. Engl. J. Med., 1997, 337(15), 1029-1036.
49. Present, D.H.; Rutgeerts, P.; Targan, S.; Hanauer, S.B.; Mayer, L.; van Hogezand, R.A.; Podolsky, D.K.; Sands, B.E.; Braakman, T.; DeWoody, K.L.; Schaible, T.F.; van Deventer, S.J. Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med., 1999, 340(18), 1398-1405.
50. Hanauer, S.B.; Feagan, B.G.; Lichtenstein, G.R.; Mayer, L.F.; Schreiber, S.; Colombel, J.F.; Rachmilewitz, D.; Wolf, D.C.; Olson, A.; Bao, W.; Rutgeerts, P. ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet, 2002, 359(9317), 1541-1549.
51. Sands, B.E.; Anderson, F.H.; Bernstein, C.N.; Chey, W.Y.; Feagan, B.G.; Fedorak, R.N.; Kamm, M.A.; Korzenik, J.R.; Lashner, B.A.; Onken, J.E.; Rachmilewitz, D.; Rutgeerts, P.; Wild, G.; Wolf, D.C.; Marsters, P.A.; Travers, S.B.; Blank, M.A.; van Deventer, S.J. Infliximab Maintenance Therapy for Fistulizing Crohn's Disease. N. Engl. J. Med., 2004, 350(9), 876-885.
52. Rutgeerts, P.; Sandborn, W.J.; Feagan, B.G.; Reinisch, W.; Olson, A.; Johanns, J.; Travers, S.; Rachmilewitz, D.; Hanauer, S.B.; Lichtenstein, G.R.; de Villiers, W.J.; Present, D.; Sands, B.E.; Co lombel, J.F. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med., 2005, 353(23), 2462-2476.
53. Colombel, J. F.; Sandborn, W. J.; Reinisch, W.; Mantzaris, G.J.; Kornbluth, A.; Rachmilewitz, D.; Lichtiger, S.; D'Haens, G.; Diamond, R.H.; Broussard, D.L.; Tang, K.L.; van der Woude, C. J.; Rutgeerts, P. SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N. Engl. J. Med., 2010, 362(15), 1383-1395.
54. Gottlieb, A.B. Tumor necrosis factor blockade: mechanism of action. J. Investig. Dermatol. Symp. Proc., 2007, 12(1), 1-4.
55. Hanauer, S.B.; Sandborn, W.J.; Rutgeerts, P.; Fedorak, R.N.; Lukas, M.; MacIntosh, D.; Panaccione, R.; Wolf, D.; Pollack, P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology, 2006, 130(2), 323-333.
56. Sandborn, W.J.; Hanauer, S.B.; Rutgeerts, P.; Fedorak, R.N.; Lukas, M.; MacIntosh, D.G.; Panaccione, R.; Wolf, D.; Kent, J.D.; Bittle, B.; Li, J.; Pollack, P.F. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut, 2007, 56(9), 1232-1239.
57. Colombel, J.F.; Sandborn, W.J.; Rutgeerts, P.; Enns, R.; Hanauer, S.B.; Panaccione, R.; Schreiber, S.; Byczkowski, D.; Li, J.; Kent, J.D.; Pollack, P.F. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology, 2007, 132(1), 52-65.
58. Sandborn, W.J.; Rutgeerts, P.; Enns, R.; Hanauer, S.B.; Colombel, J.F.; Panaccione, R.; D'Haens, G.; Li, J.; Rosenfeld, M.R.; Kent, J.D.; Pollack, P.F. Adalimumab induction therapy for Crohn's disease previously treated with infliximab: a randomized trial. Ann. Intern. Med., 2007, 146(12), 829-838.
59. Nesbitt, A.; Fossati, G.; Bergin, M.; Stephens, P.; Stephens, S.; Foulkes, R.; Brown, D.; Robinson, M.; Bourne, T. Mechanism of Action of Certolizumab Pegol (CDP870): In vitro Comparison with Other Anti-tumor Necrosis Factor α Agents. Inflamm. Bowel Dis., 2007, 13(11), 1323-1332.
60. Schreiber, S.; Khaliq-Kareemi, M.; Lawrence, I.C.; Thomsen, O.Ø.; Hanauer, S.B.; McColm, J.; Bloomfield, R.; Sandborn, W.J. PRECISE 2 Study Investigators. Maintenance Therapy with Certolizumab Pegol for Crohn's Disease. N. Engl. J. Med., 2007, 357(3), 239-250.
61. Winter, T.A.; Wright, J.; Ghosh, S.; Jahnsen, J.; Innes, A.; Round, P. Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderateto-severe Crohn's disease: an exploratory study. Aliment. Pharmacol. Ther., 2004, 20(11-12), 1337-1346.
62. Schreiber, S.; Rutgeerts, P.; Fedorak, R.N.; Khaliq-Kareemi, M.; Kamm, M.A.; Boivin, M.; Bernstein, C.N.; Staun, M.; Thomsen, O.Ø.; Innes, A. CDP870 Crohn's Disease Study Group. A Randomized, Placebo-Controlled Trial of Certolizumab Pegol (CDP870) for Treatment of Crohn's Disease. Gastroenterology, 2005, 129(3), 807-818.
63. Sandborn, W.J.; Feagan, B.G.; Stoinov, S.; Honiball, P.J.; Rutgeerts, P.; Mason, D.; Bloomfield, R.; Schreiber, S. PRECISE 1 Study Investigators. Certolizumab Pegol for the Treatment of Crohn's Disease. N. Engl. J. Med., 2007, 357(3), 228-238.
64. Rutgeerts, P.; Schreiber, S.; Feagan, B.; Keininger, D.L.; O'Neil, L.; Fedorak, R.N. CDP870 Crohn's Disease Study Group. Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFα, improves health-related quality of life in patients with moderate to severe Crohn's disease. Int. J. Colorectal Dis., 2008, 23, 289-296.
65. Clark, M.; Colombel, J.F.; Feagan, B.G.; Fedorak, R.N.; Hanauer, S.B.; Kamm, M.A.; Mayer, L.; Regueiro, C.; Rutgeerts, P.; Sandborn, W.J.; Sands, B.E.; Schreiber, S.; Targan, S.; Travis, S.; Vermeire, S. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease. Gastroenterology, 2007, 133(1), 312-339.
66. Colombel, J.F.; Rutgeerts, P.; Sandborn, W.J.; Enns, R.; Hanauer, B.S.B.; Panaccione, R.; Schreiber, S.; Byczkowski, D.; Li, J.; Kent, J.D.; Pollack, P.F. Adalimumab safety in Crohn's disease patients: open-label maintenance following the GAIN and CHARM trials. Am. J. Gastroenterol., 2007, 102(suppl. 2), S496-497.
67. Ho, G.T.; Mowat, A.; Potts, L.; Cahill, A.; Mowat, C.; Lees, C.W.; Hare, N.C.; Wilson, J.A.; Boulton-Jones, R.; Priest, M.; Watts, D.A.; Shand, A.G.; Arnott, I.D.; Russell, R.K.; Wilson, D.C.; Morris, A.J.; Satsangi, J. Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease: analysis of nationwide experience in Scotland (2004-2008). Aliment. Pharmacol. Ther., 2009, 29, 529-534.
68. Bressler, B.; Korzenik, J.R.; Canning, C.; Solomon, D.; Schneeweiss, S. Infliximab use in patients with inflammatory bowel disease and the risk of serious bacterial infections. Gastroenterology, 2008, 134(4 Suppl. 1), A-144.
69. Wallis, R.S.; Broder, M.S.; Wong, W.J.; Hanson, M.E.; Beenhouwer, D.O. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin. Inf. Dis., 2004, 38(9), 1261-1265.
70. Lin, J.; Ziring, D.; Desai, S.; Kim, S.; Wong, M.; Korin, Y.; Braun, J.; Reed, E.; Gjertson, D.; Singh, R.R. TNF alpha blockade in human diseases: An overview of efficacy and safety. Clin. Immunol., 2008, 126(1), 13-30.
71. Branton, A.J.W. Risk of infectious complications during anti-TNF therapy. Neth. J. Med., 2008, 66, 2.
72. Bongartz, T.; Sutton, A.J.; Sweeting, M.J.; Buchan, I.; Matteson, E.L.; Montori, V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA, 2006, 295(19), 2275-2285.
73. Lichtenstein, G.R.; Feagan, B.G.; Cohen, R.D.; Salzberg, B. A.; Diamond, R.H.; Chen, D.M.; Pritchard, M.L.; Sandborn, W.J. Serious infections and mortality in association with therapies for CD: TREAT registry. Clin. Gastro. Hep., 2006, 4(5), 621-630.
74. Colombel, J.F.; Loftus, E.V. Jr.; Tremaine, W.J.; Egan, L.J.; Harmsen, W.S.; Schleck, C.D.; Zinsmeister, A.R.; Sandborn, W.J. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology, 2004, 126(1), 19-31.
75. Siegel, C.A.; Marden, S.M.; Persing, S.M.; Larson, R.J.; Sands, B.E. Risk of lymphoma associated with anti-TNF agents for the treatment of Crohn's disease: A meta-analysis. Gastroenterology, 2008, 134(4 Suppl. 1), A-144.
76. Blonski, W.; Lichtenstein, G.R. Safety of biologic therapy. Inflamm. Bowel Dis., 2007, 13(6), 769-796.
77. Baert, F.; Noman, M.; Vermeire, S.; Van Assche, G.; D'Haens, G.; Carbonez, A.; Rutgeerts, P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med., 2003, 348(7), 601-608.
78. Bender, N.K.; Heilig, C.E.; Dröll, B.; Wohlgemuth, J.; Armbruster, F.P.; Heilig, B. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol. Int., 2007, 27(3), 269-274.
79. Parsi, M.A.; Achkar, J.P.; Richardson, S.; Katz, J. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology, 2002, 123, 707-713.